Late-stage cannabinoid drug development for sleep apnoea
Repurposing existing drug to de-risk R&D to commercialisation
Utilising R&D tax credits
Pre-IPO Opportunity - Intention to list within 12-18 months
Cannabinoid drug development
Program transferred from the US
Obstructive Sleep Apnoea (OSA)
Initial use case obstructive sleep apnoea followed by anorexia
Very large market opportunity
No drugs approved for OSA anywhere
De-risked drug commercialisation for millions of sleep apnoea sufferers
ResolutionRx Ltd is focused on developing and repurposing an FDA-approved drug Dronabinol in helping Obstructive Sleep Apnoea (“OSA”) sufferers to better manage their condition.
Dronabinol is a cannabinoid drug with FDA approval for the treatment of AIDS-related anorexia and chemotherapy-induced nausea and vomiting.
This re-purposing strategy should only require approval by the U.S. FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway to further approval for OSA treatment that allows the use of publicly available data.
Dronabinol, a synthetic version of ∆-9-THC, a naturally occurring substance in the cannabis plant, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials in the United States.
A serious respiratory disorder that affects millions of people globally
OSA is a serious respiratory disorder that impacts more than 90 million in Australia, the United States, Germany and the United Kingdom.
ResolutionRx Ltd was formed in Australia in January 2023 by RespireRx as an unlisted public company. RespireRx Pharmaceuticals Inc. (US OTC: RSPI) is in the process of contributing, via sublicense and license with ResolutionRx, its cannabinoid drug development program subject to certain liabilities.
ResolutionRx is engaging in the R&D associated with that program, initially for the development of a new formulation of dronabinol for use in Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnoea (“OSA”).
The current total budget for that program over the next several years is approximately A$24.8M, most, but not all of which is expected to be eligible for the R&D tax refund expected to be 43.5%.
Raising A$18M on a pre-money valuation of A$33.75M by way of series A preference shares that will convert into ordinary shares.
Funds will be used for Research and Development and General and Administrative Purposes.
- Company Presentations
Letter of Intent with Cantheon CapitalRead more
Services Agreement with iNGENu CRORead more
Entry into Letter of Intent and Term Sheet for non-dilutive financeRead more
Amendment of University of Illinois at Chicago License AgreementRead more
ResolutionRx Ltd established in AustraliaRead more
Want to learn more?
Fill in the expression of interest form below
Speak to our investment team today+61 2 9993 4475